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Outcome after autogenous brachial-axillary
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Thomas S. Huber, MD, PhD, Christa M. Hirneise, RN, W. Anthony Lee, MD, Timothy C. Flynn, MD,
and James M. Seeger, MD, Gainesville, Fla
Objective: The optimal configuration for patients with “complex” or “tertiary” hemodialysis access needs remains
undefined. This study was designed to examine the utility of the autogenous brachial-axillary translocated superficial
femoropopliteal vein access (SFV ACCESS) in this subset of patients.
Methods: Patients presenting for permanent hemodialysis access without a suitable upper extremity vein for autogenous
access identified by duplex ultrasound mapping and those with repeated prosthetic access failures were considered
candidates for SFV ACCESS. Ankle-brachial indices were obtained, and duplex scanning of the superficial femoropop-
liteal and saphenous veins was performed. Patients deemed candidates for SFV ACCESS also underwent preoperative
upper extremity arteriography and venography. A retrospective review of the complete medical record was performed,
and a follow-up telephone or personal interview was conducted.
Results: Thirty patients (mean age  SD, 54  15 years; male, 33%; white, 37%; with diabetes, 50%; obese, 21%)
underwent SFV ACCESS among approximately 650 access-related open surgical procedures during the study period. The
patients had been receiving dialysis for 4  5 years (range, 0-24 years), and had 3  3 (range, 0-17) prior permanent
accesses, whereas 90% were actively dialyzed through tunneled catheters. In-hospital 30-day mortality was 3%, and the
hospital length of stay was 7  7 days. Fifty-seven percent of the patients experienced some type of perioperative
complication, and 38% required a remedial surgical procedure. Hand ischemia developed in 43% of the patients (severity
grade: 1, 10%; 2, 7%; 3, 27%), and a distal revascularization, interval ligation was performed in all those with grade 3
ischemia. Thigh wound complications or hematomas developed in 23% of the patients, and arm wound complications or
hematomas developed in 17%. The incidence of thigh wound complications was significantly greater (57% vs 9%; P .03)
in obese patients, but the other perioperative complications analyzed could not be predicted on the basis of age, gender,
or comorbid conditions. The SFV ACCESS was cannulated 7  1 weeks postoperatively. The primary, primary assisted,
and secondary patency rates were 96%  4%, 100%  0%, and 100%  0%, respectively, at 6 months; 79%  8%, 91% 
6%, and 100%  0%, respectively, at 12 months; and 67%  13%, 86%  9%, and 100%  0%, respectively, at 18 months
(life table analysis; %  SE).
Conclusions: The intermediate term functional patency rate after SFV ACCESS is excellent, although the magnitude of the
procedure and the complication rate are significant. SFV ACCESS should only be considered in patients with limited
access options. (J Vasc Surg 2004;40:311-8.)The National Kidney Foundation Clinical guidelines
for vascular access (Dialysis Outcome and Quality Initia-
tive) have helped define the algorithms for patients requir-
ing permanent hemodialysis access and have emphasized
the benefits of autogenous configurations.1 The Dialysis
Outcome and Quality Initiative recommends the autoge-
nous radiocephalic and brachiocephalic accesses as their
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doi:10.1016/j.jvs.2004.04.018first two choices, and state that the third option should be
either an autogenous brachiobasilic or prosthetic access.
The optimal access configuration in patients with inade-
quate peripheral veins for autogenous access and those with
multiple previous prosthetic failures remains undefined.
This subset of patients with “complex” or “tertiary” access
problems poses a difficult challenge in terms of maintaining
sufficient access to ensure adequate dialysis while minimiz-
ing access-related complications. Unfortunately, this subset
of patients will likely increase, given the expanding popu-
lation of patients with end-stage renal disease (ESRD) and
their improved life expectancy. Indeed, the United States
Renal Data System reported that there were approximately
250,000 patients receiving hemodialysis in 2000, including
94,000 new patients, while the mean life expectancy for
patients with ESRD between 50 and 54 years of age is
greater than 5 years.2 We have previously described using
the superficial femoropopliteal vein to construct an autog-
enous brachial-axillary access (SFV ACCESS) in a patient
with limited autogenous options considered a poor candi-311
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examine the utility of the SFV ACCESS in a larger series of
patients with complex hemodialysis access needs.
METHODS
Experimental design. Patients who underwent SFV
ACCESS between November 1998 and December 2003
were identified from the vascular registry in the Division of
Vascular and Endovascular Therapy at the University of
Florida College of Medicine. A retrospective review of the
outpatient clinic and the hospital medical records, includ-
ing the admitting history and physical examination, the
inpatient progress notes, the operative report, and the
noninvasive and invasive imaging studies was performed,
and a comprehensive database was generated. In addition,
the study patients or their respective dialysis units were
interviewed either in person or by telephone to confirm the
current status of the access and to identify any additional
problems.
Preoperative evaluation. Patients referred to the vas-
cular surgery service for permanent access were evaluated
with our previously published algorithm designed to opti-
mize the use of autogenous access.4 In brief, patients
underwent upper extremity arterial and venous noninvasive
vascular laboratory testing as the initial step. The arterial
studies included pressure measurements and waveform
analyses of the brachial, radial, and ulnar arteries, in addi-
tion to diameter measurements of the brachial and radial
vessels at the elbow and wrist, respectively. The venous
noninasive imaging included assessment of both the diam-
eter and quality of the cephalic and basilic veins from the
wrist to the axilla, and interrogation of the axillary and
subclavian veins, to rule out thromboses. The criteria used
to determine whether the artery and vein were suitable for
constructing an autogenous access included no hemody-
namically significant arterial inflow stenosis, an arterial di-
ameter greater than 2 mm, a nondominant radial artery, a
peripheral vein greater than 3 mm in diameter that spanned
the length of the forearm or arm, and the absence of a
central vein occlusion in the ipsilateral extremity. The au-
togenous access options included the radiocephalic, radio-
basilic, brachiocephalic, and brachiobasilic configurations,
in descending order of preference. Patients with suitable
arterial inflow and venous outflow on the ipsilateral extrem-
ity, but without an acceptable peripheral vein for an autog-
enous access were considered candidates for prosthetic
access with the brachial artery in either a brachial-antecu-
bital (forearm loop) or brachial-axillary configuration. The
subset of patients without autogenous access options and
those with relative contraindications for a prosthetic access,
usually because of a history of multiple prosthetic access
failures from early thrombosis or infection, deemed at
acceptable surgical risk were additionally considered for
SFV ACCESS. These patients underwent further noninva-
sive imaging to confirm that the superficial femoropopliteal
vein was a suitable conduit, to confirm that the lower
extremity arterial circulation was sufficient to heal the vein
harvest incision (popliteal pressure 50 mm Hg), and todetermine that the saphenous vein was suitable to be used
as a composite vein if the superficial femoropopliteal vein
was not sufficient or as a conduit for a distal revasculariza-
tion–interval ligation (DRIL) procedure if postoperative
hand ischemia developed.5 The lower extremity arterial
studies included pressure measurements with determina-
tion of ankle-brachial indices and waveform analyses with
continuous- wave Doppler scanning interfaced with an
analog recording device (IMEX). The diameter and quality
of the saphenous vein6 and the superficial and femoral
popliteal veins were examined with duplex ultrasound scan-
ning. The deep veins were examined from the confluence of
the tibial veins to the common femoral vein with an 8-MHz
probe (Advanced Technology Laboratory) with the same
technique used to look for deep venous thromboses. Su-
perficial femoropopliteal vein segments were considered
suitable for SFV ACCESS if their diameter was greater than
6 mm from the midpopliteal fossa to the termination at the
confluence of the profunda femoral vein and there were no
intraluminal defects. The arterial inflow and venous out-
flow on the upper extremity selected for the SFV ACCESS
were further interrogated with standard contrast material–
enhanced arteriography and venography to definitively
confirm that there were not significant lesions, per the
published algorithm.
Operative technique3 (Fig 1). General endotracheal
anesthesia was used for all the SFV ACCESS procedures.
The patients were positioned with the upper extremity
abducted to 90 degrees and positioned on a “hand table”
extension. The operative field included the upper extremity
and axilla, and both lower extremities. A 3-cm segment of
the brachial artery was exposed immediately proximal to
the antecubital fossa through a longitudinal incision. A
similar length of axillary vein was exposed through a longi-
tudinal incision starting in the proximal arm and extending
into the axilla. It was usually necessary to remove all previ-
ous prosthetic accesses in the arm to facilitate exposure of
the desired vessels and to create the tunnel for the vein
graft. The superficial femoropopliteal vein was exposed
through an incision that extended from the inferior aspect
of the femoral triangle over the common femoral vein to
the above-knee popliteal fossa on the lateral aspect of the
sartorius muscle. The proximal and distal aspects of the
thigh incision comprised those traditionally used for expo-
sure of the common femoral and above-knee popliteal
vessels, respectively. Alternatively, the vein can be exposed
through an incision lateral to the sartorius muscle that
extends from the proximal thigh to the knee. The superfi-
cial femoropopliteal vein was then dissected free caudally
from its confluence with the profunda femoral vein to the
midpopliteal fossa. Complete exposure of vein required
incising the adductor canal and retracting the sartorius
muscle. The multiple branches of the superficial femoro-
popliteal vein were ligated, with care to preserve the adja-
cent unnamed collateral arterial branches. The superficial
femoropopliteal vein was excised flush with the profunda
femoral vein to avoid any potential nidus for thrombus and
immediately behind the patella in the midpopliteal fossa. A
ccess.
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technique, and this is usually sufficient to construct a bra-
chial-axillary access that includes a generous lateral curve
over the biceps muscle. The lumen of the vein was imaged
with the angioscopy, and all defects were repaired. The
tunnel in the arm was created with a 6-mm semicircular
tunneller, and the vein was passed through the tunnel
nondistended and in reverse orientation to maintain ante-
grade flow through the vein relative to its valves. The
proximal and distal anastomoses were performed with 6-0
and 5-0 monofilament suture, with loupe magnification,
after systemic heparinization. The access and the ipsilateral
upper extremity pulses were interrogated by both physical
examination and continuous wave Doppler scanning. Of
note, the traditional thrill used to confirm the adequacy of
the access was not always present in the SFV ACCESS,
presumably because of the size of the vein, despite no
technical defects and a patent ipsilateral central vein. Two
No. 10 Jackson-Pratt drains were placed in the bed of the
superficial femoropopliteal vein harvest, and brought out
through separate stab wounds immediately above the knee.
The vein harvest incision was closed in two layers, and the
heparin effect was reversed with protamine if there was
evidence of coagulopathic bleeding.
Symptomatic hand ischemia was treated with the DRIL
procedure. Both the original arm incisions, that is, brachial
and axillary, were extended to expose the brachial artery,
and a tunnel was created between the intervening soft
tissues. The proximal anastomosis for the DRIL procedure
was sited on the brachial artery 10 cm proximal to the access
anastomosis, and the distal anastomosis for the DRIL was
sited immediately distal to the access anastomosis.
Fig 1. Original artist rendition of the autogenous brach
(SFV ACCESS) depicts a composite configuration with
has rarely been necessary in our more recent experience.
a mature brachiocephalic autogenous access. (From Hu
superficial femoral vein for hemodialysis arteriovenous aPostoperative care. Patients were admitted to the
hospital after the procedure, and were closely monitored
for the development of hand ischemia, wound infection or
breakdown, and compartment syndrome. Patients with
mild to moderate (grade 1-27) hand ischemia were man-
aged expectantly, and those with severe (grade 3) ischemia
underwent the DRIL procedure. Patients were discharged
when they were ambulatory, their incisional pain was under
control with oral medications, and they were able to care
for themselves. The Jackson-Pratt drains were removed
when the output decreased to less than 50 mL per 8 hours,
which was usually on the second postoperative day. Patients
were followed up in the outpatient clinic biweekly until
their wounds were healed and they could be successfully
dialyzed through the SFV ACCESS. No set criteria were
used to determine when the access was suitable for cannu-
lation. Patients were not routinely seen in the outpatient
clinic over the long term unless they had undergone a
DRIL procedure. These patients were followed up at spe-
cific intervals with duplex ultrasound scanning of the bypass
graft, similar to those patients undergoing infrainguinal
arterial reconstruction. Patients in whom problems devel-
oped during dialysis from either reduced flow or elevated
venous pressure underwent fistulography and remedial
treatment with either balloon angioplasty or open surgical
revision (vein patch angioplasty or interposition graft).
Patients with thrombosed accesses underwent initial chem-
ical lysis before endovascular or surgical revision.
Analyses and statistics. The primary, primary as-
sisted, and secondary functional patency rates for the SFV
ACCESS were reported with life table methods.8 All con-
tinuous data were reported as the mean value SD. Patient
illary translocated superficial femoropopliteal vein access
nous and superficial femoropopliteal vein, although this
ted in the text, the SFV ACCESS has the appearance of
S, Ozaki CK, Flynn TC, Ross EA, Seeger JM. Use of
J Vasc Surg 2000;31:1038-41. Used with permission).ial-ax
saphe
As no
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.05 was accepted as significant. The Health Center Institu-
tional Review Board at the University of Florida approved
the study (No. 332-2003).
RESULTS
A total of 30 patients underwent SFV ACCESS during
the study period, among approximately 650 access-related
open surgical procedures. The mean patient age was 54 
15 years, and most patients (67%) were women or African
American (63%); a significant proportion had diabetes
(50%) or were obese (21%; 125% ideal body weight).
Diabetes (43%) and hypertension (23%) were the leading
causes of ESRD. The patients had been receiving dialysis
for 4  5 years (range, 0-24 years), and had undergone on
average 3  3 (range, 0-17) previous permanent hemodi-
alysis access procedures. The overwhelming majority of the
patients were actively dialyzed through tunneled catheters
(tunneled hemodialysis catheter, 90%; peritoneal dialysis
catheter, 3%; prosthetic hemodialysis access, 7%).
The 30-day-in-hospital mortality rate was 3%, and the
60-day mortality rate was 7%. Of note, the mortality for all
open surgical access-related procedures at our institution
over the past 13 months was 3.6%. One patient in the
current study died before discharge, of respiratory arrest,
and a second patient was readmitted in the early postoper-
ative period with wound problems and had a fatal arrhyth-
mia. Fifty-seven percent of the patients experienced some
type of perioperative complication, and 38% required some
type of remedial surgical procedure as a result of the com-
plication. Significant hand ischemia developed in 43% of
the patients (severity score 1 [mild], 10%; 2 [moderate],
7%; 3 [severe], 27%), and required a DRIL procedure in
27%, or all those with a severity score of 3. There were no
significant differences in the incidence of hand ischemia
Fig 2. Primary, primary-assisted, and secondary life table curves
and their corresponding negative standard error bars are shown for
the SFV ACCESS. The standard error exceeds 10% at 15 and 18
months, respectively, for the primary and primary-assisted patency
rates. Complete life table data are provided in Tables I through III,
online only.between patients with or without diabetes (47% vs 40%),
male or female patients (20% vs 55%; P .12), and patients
older or younger than 65 years (29% vs 48%). Of note, three
fourths of the DRIL procedures were performed within the
first postoperative month. Thigh wound complications or
hematomas developed in 23% of the patients, and arm
wound complications or hematomas developed in 17%.
There was a significant difference in the incidence of thigh
complications or hematomas between obese and nonobese
patients (57% vs 13%; P  .03), but not for arm complica-
tions or hematomas (42% vs 9%; P  .07). Calf compart-
ment syndrome developed in two patients (7%), necessitat-
ing a fasciotomy ipsilateral to the superficial
femoropopliteal vein harvest. Of note, the saphenous vein
was harvested for a DRIL procedure ipsilateral to the
superficial femoropopliteal vein harvest in one of these
patients. The mean hospital length of stay after the SFV
ACCESS was 7  7 days, and 7% of the patients were
subsequently readmitted because of some type of perioper-
ative complication, for a total postoperative length of stay
of 9  12 days. The SFV ACCESS was initially cannulated
for dialysis at 7  1 weeks postoperatively.
The primary, primary assisted, and secondary patency
rates for the SFV ACCESS were 96%  4%, 100%  0%,
and 100% 0%, respectively, at 6 months; 79% 8%, 91%
 6%, and 100% 0%, respectively, at 12 months; and 67%
 13%, 86%  9%, and 100%  0%, respectively, at 18
months (Fig 2; Tables I-III, online only). The three ac-
cesses that thrombosed were all successfully treated with
chemical lysis. No identifiable cause for the thrombosis was
found in one patient, whereas critical stenoses were found
in the superficial femoropopliteal vein segment in the other
two patients and required open surgical revision (interpo-
sition graft, vein patch angioplasty). The procedures to
maintain patency among the “failing” accesses with critical
stenoses included balloon angioplasty (n 2) and interpo-
sition grafting (n  3) in the superficial femoropopliteal
vein segment or central veins. Both patients (7%) with
compartment syndrome experienced moderate to severe
leg edema (severity score, 27), and 50% of the patients
complained of mild pain, numbness, or edema (severity
score, 1) in the extremity ipsilateral to the deep vein har-
vest. One patient (3%) with moderate peripheral vascular
occlusive disease required an above-knee amputation ipsi-
lateral to the deep vein harvest, and a second patient (3%)
with a known ipsilateral central vein occlusion had moder-
ate arm edema (severity score, 1). In one patient with a
“failing” DRIL procedure who refused follow-up digital
gangrene developed, which required a finger amputation.
DISCUSSION
The intermediate-term functional patency rate for the
SFV ACCESS is excellent, although the procedure is asso-
ciated with a significant cost in terms of perioperative
morbidity and mortality. The patency rate is comparable to
that reported for other autogenous accesses, and signifi-
cantly better than that usually reported for prosthetic con-
duits. Of note, we recently reported a systematic review of
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ity accesses in adults, and found that the 12-month primary
patency rate was approximately 60% for autogenous con-
figurations and 40% for polytetrafluoroethylene (PTFE),
with corresponding secondary patency rates of 80% and
60%, respectively.9 The results of our current series are even
more impressive, given that the patient population had
complex access problems with limited options and multiple
previous procedures. The studies that composed our sys-
tematic review did not consistently report perioperative
complications in a standard fashion; however, there were
few perioperative deaths (median, 0%; range, 0%-1%), and
both the hand ischemia (median, 2%; range, 0%-14%) and
access-related infectious complications (median, 7%; range,
0%-30%), which comprised two of the largest individual
complications, were also low. This is in stark contrast to our
current report, with its 3% in-hospital 30-day mortality rate
and 57% overall complication rate, which includes a 27%
rate of DRIL procedures for hand ischemia.
We have maintained a significant amount of enthusiasm
for the SFV ACCESS despite the associated complications,
and contend that the characteristics of the vein and the
excellent patency rates justify the procedure. The mean
diameter of the superficial femoropopliteal vein in adults is
7 mm at its mid-portion,10 and the wall is thick relative to
either the basilic or cephalic vein. Indeed, the SFV AC-
CESS has the appearance and handling characteristics of a
mature, arterialized brachiocephalic autogenous access.
Most of the complications associated with the SFV AC-
CESS, with the obvious exception of perioperative death,
are remediable and associated with reasonable long-term
outcomes. Admitted, the complications prolong hospital
stay and require additional health care resources, and costs,
in terms of subacute care facilities or visiting nurses. In
addition, the long-term patency rate for the DRIL proce-
dure remains undefined, and, despite our enthusiasm, the
published experience is less than 200 procedures.5,11-15 It
is also disturbing that the perfusion to the affected hand
after a DRIL procedure is completely dependent on the
brachial artery bypass. Last, the mortality in the current
study, although significant, was comparable to that for our
access practice as a whole, and attests to the fact that
patients with ESRD are at modest operative risk despite
what seems to be a fairly minimal procedure. Indeed, the
annual unadjusted death rate for all patients with ESRD
across the United States is 177.6 per 1000 patient-years at
risk.16
We concede that the role of the SFV ACCESS in
patients with complex access problems is debatable in light
of the associated morbidity and mortality, given that there
are other access alternatives. Essentially all of the patients in
our series could have received a brachial-axillary prosthetic
access (or an additional brachial-axillary prosthetic access),
a tunneled catheter, or a femorofemoral inguinal access
with either autogenous or prosthetic conduit. Further-
more, we have reported that all that is necessary to con-
struct a permanent hemodialysis access is an arterial inflow
site, a venous outflow site, and some type of conduit,12whereas the literature is replete with a variety of “heroic”
configurations.17 The study patients were considered for
SFV ACCESS only if we thought they would not derive
significant additional benefit from a brachial artery–based
prosthetic access, although this is subjective. Furthermore,
the use of temporary catheters increases the mortality for
patients with ESRD relative to autogenous or prosthetic
accesses,18-20 while the infectious complications of thigh
prosthetic accesses are significant and may be prohibi-
tive.21-24 Cull et al25 recently reported that the incidence of
infectious complications after 125 prosthetic thigh accesses
was 41% and the 2-year primary patency rates were only
19%, and concluded that tunneled catheters are a superior
option. Of note, Jackson25 and Gradman et al26 reported
transposing the superficial femoral vein in the thigh to
create an autogenous access. The patency rates reported by
Gradman et al26 were excellent (12 months: primary, 73%;
secondary, 86%), although the complication rates (major
wound, 28%; remedial procedure to treat ischemia, 32%;
major amputation, 4%) were significant and comparable to
those in our series. In addition, the long-term outcome
after many of the heroic options remains to be defined, and
may represent little more than short-term solutions.
The algorithm defining our hierarchy of access config-
urations outlined in the Methods section reflects our cur-
rent practice, although the results of the study have forced
us to reexamine the indications for the SFV ACCESS. The
net effect is that we have become somewhat more conser-
vative about recommending the procedure. Our univariate
analyses did not enable us to identify the subsets of patients
at risk for hand or wound complications, with the exception
of the increased incidence of thigh complications in obese
patients. We presently reserve the procedure for patients
who are compliant, at good operative risk, with a reason-
able life expectancy, and with a suitable segment of saphe-
nous vein that could be used for a DRIL procedure. Pa-
tients must be compliant, because those who require a
DRIL procedure need long-term follow-up of the graft. It
is likely that we could have prevented the digital amputa-
tion in the patient with the “failing” DRIL procedure had
we known that she was having problems. There are no
specific criteria to define “good risk” other than plain
surgical judgment. The patient’s cardiac and pulmonary
systems should be sufficient to tolerate a major operation.
We have weighed the known preoperative risk factors for
developing hand ischemia after a brachial artery–based
access into our decision process, including female gender,
peripheral vascular occlusive disease, age, and diabetes. The
preoperative noninvasive and invasive arterial imaging stud-
ies have helped identify any significant arterial occlusive
disease. However, none of the patients in whom hand
ischemia developed had any evidence of discrete, hemody-
namically significant arterial inflow lesions, and few had any
evidence of forearm disease. We have hypothesized that the
hand ischemia results from the fact that the compensatory
changes in the arterial inflow are insufficient to overcome
the decrease in resistance from the fistula, and that the
resultant decrease in arterial pressure is further exacerbated
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quantify the flow through the SFV ACCESS, but would
hypothesize that it is significant and likely greater than with
PTFE or other non-autogenous biologic conduits. Of
note, Matsuura et al27 reported a 3% incidence of hand
ischemia with PTFE brachial-axillary accesses and a 2%
incidence for cryopreserved femoral vein grafts in the same
location. We have also factored the patient’s weight and
body habitus into the decision algorithm, because of the
significant incidence of wound complications. Harvesting
the superficial femoropopliteal vein is substantially more
challenging in obese patients, and is associated with a
greater incidence of thigh wound complications. Indeed,
most of the prolonged hospital stays after the SFV ACCESS
were due to thigh wound complications. It has been our
impression that placing the Jackson-Pratt drains helps elim-
inate the anatomic dead space after the harvest and pro-
motes apposition of the tissues. Last, the criterion that
patients have a reasonable life expectancy simply represents
an attempt to balance the cost of the procedure in terms of
the perioperative morbidity and mortality and the benefit in
terms of a successful access.
There are several points regarding the study and the
procedure that merit further comment. First, the long-term
follow-up is somewhat limited. The standard error for the
life table data exceeded 10% (a reliability threshold for the
life table method) after 15 and 18 months for the primary
and primary-assisted patency rates, respectively. It is impos-
sible to determine how the SFV ACCESS will hold up
beyond the time frame of the study. However, the patency
for all prosthetic and autogenous access procedures is
somewhat limited, and usually quoted in the 6-month to
18-month range. Second, there are several available treat-
ment options for patients with hand ischemia other than
the DRIL procedure, including simple ligation and band-
ing. We have felt compelled to salvage the SFV ACCESS in
patients in whom hand ischemia developed, given the mag-
nitude of the procedure, although our first priority is clearly
to maintain a normal, functional hand. Our enthusiasm for
any type of banding procedure is somewhat limited, al-
though we have had some anecdotal success in other set-
tings in patients with persistent hand ischemia despite a
successful DRIL procedure.28 Third, we have not devel-
oped a formal surveillance plan, nor have we routinely seen
patients in the clinic long-term after the SFV ACCESS,
with the exception of those who have undergone a DRIL
procedure. However, we have established a nice relation-
ship and open lines of communications with the surround-
ing dialysis centers, and maintain a low threshold for ob-
taining a fistulogram if there is any concern about the
integrity of the SFV ACCESS. Fourth, we have become
reluctant to harvest the saphenous vein ipsilateral to the
superficial femoropopliteal vein harvest, and vice versa in
patients in whom the the saphenous vein has been har-
vested, because of the potential for development of signif-
icant venous hypertension or a compartment syndrome,
despite the fact that the profunda femoris vein is reportedly
the main collateral vessel for the superficial femoropoplitealvein.29 Last, we have considered an ipsilateral central vein
occlusion only a relative contraindication to SFV ACCESS.
We have been impressed with the number of patients in our
access practice (not just patients with an SFV ACCESS)
with a patent, functional access and an ipsilateral central
vein occlusion who do not have significant arm edema.
Furthermore, we have been impressed that, when we have
placed a new access in patients with an ipsilateral central
vein occlusion, few have had significant, persistent arm
edema that requires dissembling the access. However, we
would proceed with an SFV ACCESS in the presence of a
known central vein occlusion only after a prosthetic brachi-
al-axillary access failed, presuming that the arm edema was
manageable.
In conclusion, the functional patency rates after SFV
ACCESS are excellent, although the magnitude of the
procedure and the complication rates are significant. SFV
ACCESS should be considered only in patients with limited
access options.
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at www.mosby.com/jvs.DISCUSSIONDr David L. Cull (Greenville, SC). Traditionally, the patency
rate has been considered the most important outcome measure for
arteriovenous access procedures. Using this standard, the autoge-
nous brachial-axillary arteriovenous (AV) access with SFV is an
exceptional procedure, since the patency results obtained by Dr
Huber were superb. We must, however, carefully consider the cost
and morbidity of this procedure in determining its role in relation
to other tertiary AV access procedures such as the prosthetic thigh
or chest wall arteriovenous access.
To achieve these results Dr Huber’s group performed an
extensive preoperative work-up. Despite the obvious care under-
taken to ensure good outcomes for these patients, the complica-
tion rate was significant. Fifty-seven percent of patients suffered a
perioperative complication, and 38% required a remedial opera-
tion. Most concerning was a 43% incidence of arterial steal, which
was significant enough to require a DRIL procedure in 27% of
patients.
I have the following questions for the authors. To perform this
procedure you must use vein from 2 potential sites for AV access
placement, the leg and the arm. Are you concerned that harvest of
the SFV will preclude future AV access placement in that thigh? If
so, would these patients have been better off receiving a prosthetic
upper arm access, then a prosthetic thigh access when the arm
access failed? Three years ago, Gradman reported a series of pa-
tients who underwent superficial femoral vein transposition in the
thigh for AV access. He reported secondary patency results similar
to yours. Given his results and the problems with steal in the upper
extremity, why not transpose the superficial femoral vein in the
thigh rather than moving it to the arm? Finally, with your extensive
experience with this procedure, what lessons can you give us
regarding minimizing the incidence of these complications. For
example, have you changed your patient selection criteria? Have
you changed your technique, such as limiting the length of the
arterial anastomosis? To do so might decrease your patency rate;
however, it might also reduce the incidence of arterial steal.
Dr Thomas S. Huber. I would say that our group has
maintained a fair amount of enthusiasm for the procedure, and I
would contend that this is based on the excellent patency rates in a
very difficult subset of patients. These are truly patients without
any other access options. The deep vein behaves just like a mature,arterialized brachiocephalic fistula. It is about 7 to 10 mm in
diameter and it’s a very thick-walled, sturdy vein. We have con-
formed pretty strictly to our previously published algorithm. All
the patients presenting for access are evaluated for some autoge-
nous access and the majority of the patients in our practice have an
autogenous option. In those who are not candidates, we use
prosthestic accesses much like everyone else. Most of the patients
in this setting cannot have a forearm access because the bridge has
usually been burned. The patients who received an SFV access in
our algorithm were those who we thought could not have another
piece of plastic in their arm. That’s the subset of patients that we are
talking about. Yes, we have burned a few bridges conceivably, but
these are patients that we deemed very poor candidates for addi-
tional prosthetic accesses in their arms. The other options are
certainly tunneled catheters forever or thigh access. Our enthusi-
asm for thigh access has been somewhat limited. The experience in
the literature is variable, with infectious complication rates ranging
up to 40% or 50%.
So what have we learned from this experience? Part of the
motivation for the study was to go back and look at our experience
for our own benefit to find out how well we are doing. On the basis
of what we have learned, we have become a little more conserva-
tive. I think the SFV access is an appropriate access for compliant,
good risk patients with reasonable life expectancy who have a
suitable piece of saphenous vein in case a DRIL procedure is
necessary. The patients must be compliant because they have to
come back to clinic. We could have prevented the 1 woman from
losing her finger if she had come back to clinic. The patients must
be a good surgical risk because the magnitude of the procedure is
comparable to femoropopliteal bypass. We consider the preopera-
tive risk factors for hand ischemia, including arterial occlusive
disease or diabetes, gender, and age, even though they didn’t shake
out as predictors in our own experience. We have also been a little
more conservative about recommending it in obese patients be-
cause of the wound complication rate. I don’t think that minimiz-
ing the arterial anastomosis makes any real impact. There is a very
nice chapter in one of standard access textbooks outlining the
physics involved with the access flow, and unless you narrow your
anastomosis more than 75% the arterial diameter you don’t really
limit the flow through that anastomosis, so that hasn’t been
particularly beneficial. And I must say, despite our incidence of
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They didn’t have any obvious arterial inflow problems and very few
of them had any forearm vascular disease.
The other questions concerned whether we precluded people
from getting thigh accesses. I don’t think so. We harvest the
SFV/popliteal vein from the confluence of the deep vein to imme-
diately behind the knee, but patients could certainly have thigh
accesses based off the common femoral vein and the common
femoral artery. Admittedly, it might bit a little more difficult to
make the tunnel because of the incision.
The other question that you asked was our experience with
thigh deep vein accesses. Early in our experience, we had some
really bad outcomes with this configuration due to wound break-
down. The grafts became exposed and the patients developed
ischemic complications of the leg. We have really backed away from
that configuration. However, it may be worthwhile revisiting it in
the future.
Dr Kenneth McIntyre (Las Vegas, NV). I am interested in
how long it takes you to do this procedure? Wayne Gradman takes
a piece of PTFE on the arterial inflow side and buries it deep to the
muscle. He uses the SFV transposed into the superficial position so
that the part that is stuck by the dialysis technicians is in the
superficial position. I think that this composite graft offers some
real possibility.
Dr Huber. As I mentioned, perhaps it’s time to go back to
those options. As far as the time, it takes somewhere between 2 to
3 hours to perform the operation. The brachial artery and axillary
vein dissection are a piece of cake and take about 30 or 40 minutes.
Harvesting the deep vein takes somewhere between an hour to anhour and a half. Furthermore, it is helpful to have an assistant to
help tie the multiple branches.
Dr McIntyre. But you were doing it just with 1 team?
Dr Huber. We use a single team. The arm exposure is
performed first and then the deep vein harvest.
Dr W. Charles Sternbergh (New Orleans, La). I enjoyed
your paper. I have a comment about your preoperative evaluation.
Clearly, your use of arteriography and venography is substantial
and much more than the average dialysis-access patient receives.
Perhaps your great patency rates are due in part because of this
exhaustive preoperative evaluation. You may have excluded occult
vascular problems that we all occasionally miss. Of people who
were potential candidates for this, whom you subjected to arteriog-
raphy and venography, what percentage was found to be unsuit-
able because of occult vascular problems?
Dr Huber. I’m not certain I can answer that specifically for
this subset of patients. As I said earlier, a couple of years ago we
presented our access algorithm, which is basically the same one we
used for this study. We found that there was some type of abnor-
mality on the arteriograms and venograms in 40% of the people and
that 20% of the time these findings had an impact on what we did
as far as our operative plan. The majority of the patients had more
forearm vascular disease than we had appreciated and you might
predict from our diabetic population. We have become more
reliant on the noninvasive imaging and obtain fewer arteriograms
with the exception of people that have known vascular disease or
diabetes. As far as venography, we likewise have backed away from
it and have been impressed with the fact that central vein occlusion
or central vein stenosis is only a relative contraindication to ipsilat-
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